$426.49 Million in Sales Expected for Amedisys Inc (AMED) This Quarter

Share on StockTwits

Wall Street analysts expect that Amedisys Inc (NASDAQ:AMED) will post sales of $426.49 million for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Amedisys’ earnings, with the highest sales estimate coming in at $431.10 million and the lowest estimate coming in at $419.70 million. Amedisys posted sales of $404.24 million during the same quarter last year, which indicates a positive year over year growth rate of 5.5%. The firm is expected to issue its next earnings report after the market closes on Wednesday, February 27th.

According to Zacks, analysts expect that Amedisys will report full year sales of $1.66 billion for the current year, with estimates ranging from $1.65 billion to $1.66 billion. For the next fiscal year, analysts anticipate that the company will post sales of $1.81 billion, with estimates ranging from $1.74 billion to $1.93 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Amedisys.

A number of brokerages have recently commented on AMED. Benchmark downgraded Amedisys from a “buy” rating to a “hold” rating and set a $136.64 price objective for the company. in a research report on Tuesday, February 5th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $151.00 price objective for the company in a research report on Thursday. ValuEngine upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 4th. Craig Hallum downgraded Amedisys from a “buy” rating to a “hold” rating and cut their price objective for the company from $116.00 to $104.00 in a research report on Friday, October 26th. Finally, BidaskClub upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 8th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Amedisys presently has an average rating of “Buy” and an average target price of $114.62.

In other news, insider Michael Paul North sold 5,625 shares of the stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $117.57, for a total value of $661,331.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David B. Pearce sold 410 shares of the stock in a transaction on Monday, December 24th. The shares were sold at an average price of $106.61, for a total value of $43,710.10. Following the completion of the sale, the insider now owns 11,010 shares of the company’s stock, valued at approximately $1,173,776.10. The disclosure for this sale can be found here. Insiders sold 12,952 shares of company stock valued at $1,587,677 in the last 90 days. Corporate insiders own 2.60% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in shares of Amedisys by 0.6% in the fourth quarter. BlackRock Inc. now owns 5,020,723 shares of the health services provider’s stock worth $587,979,000 after acquiring an additional 28,382 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Amedisys by 14.3% in the third quarter. Vanguard Group Inc. now owns 3,326,180 shares of the health services provider’s stock worth $415,640,000 after acquiring an additional 415,060 shares during the last quarter. Vanguard Group Inc increased its stake in shares of Amedisys by 14.3% in the third quarter. Vanguard Group Inc now owns 3,326,180 shares of the health services provider’s stock worth $415,640,000 after acquiring an additional 415,060 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Amedisys by 14.6% in the third quarter. JPMorgan Chase & Co. now owns 934,137 shares of the health services provider’s stock worth $116,731,000 after acquiring an additional 118,936 shares during the last quarter. Finally, Acadian Asset Management LLC increased its stake in shares of Amedisys by 31.6% in the fourth quarter. Acadian Asset Management LLC now owns 802,138 shares of the health services provider’s stock worth $93,940,000 after acquiring an additional 192,552 shares during the last quarter. 96.45% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:AMED traded up $1.71 on Monday, reaching $132.06. 244,800 shares of the company traded hands, compared to its average volume of 315,161. Amedisys has a fifty-two week low of $54.06 and a fifty-two week high of $140.91. The company has a market capitalization of $4.17 billion, a PE ratio of 59.76, a price-to-earnings-growth ratio of 1.72 and a beta of 1.43. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.06 and a current ratio of 1.06.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Featured Story: Cost of Capital

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Gentex Co.  Position Lifted by Stevens Capital Management LP
Gentex Co. Position Lifted by Stevens Capital Management LP
A. O. Smith Corp  Shares Sold by Stevens Capital Management LP
A. O. Smith Corp Shares Sold by Stevens Capital Management LP
Stevens Capital Management LP Raises Holdings in Centene Corp
Stevens Capital Management LP Raises Holdings in Centene Corp
Unitil Co.  Holdings Boosted by Teachers Advisors LLC
Unitil Co. Holdings Boosted by Teachers Advisors LLC
Verition Fund Management LLC Purchases Shares of 35,453 PepsiCo, Inc.
Verition Fund Management LLC Purchases Shares of 35,453 PepsiCo, Inc.
Pfizer Inc.  Shares Bought by Twin Capital Management Inc.
Pfizer Inc. Shares Bought by Twin Capital Management Inc.


Leave a Reply

 
© 2006-2019 Zolmax.